Global X FTSE Andean 40 ETF AND
Set alert
No live quote for AND yet.
- Open
- 0.00
- Prev close
- 16.27
- Mkt cap
- 0
- Vol
- 0
- Avg vol
- 0
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 16.27
- High
- 16.27
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 1.00
- 200-d avg
- 1.00
News
-
3 months ago benzinga.com
Teva Pharmaceuticals International Granted Exclusive Rights To Commercialize Formulations For Polpharma Biologics’ Proposed Biosimilar To Ocrevus
Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd (NYSE:AND) and Polpharma Biologics International AG today announced a global licensing agreement granting…
-
3 months ago benzinga.com
Teva Pharma And Polpharma Biologics Announce Global Licensing Agreement Granting Teva Exclusive Rights To Commercialize Both Formulations Of Polpharma Biologics’ Proposed Biosimilar To Ocrevus, Upon Regulatory Approval
Teva secures exclusive global rights to commercialize Polpharma Biologics’ biosimilar candidate to Ocrevus® (ocrelizumab), including both intravenous and subcutaneous formulations.Agreement advances…
-
5 months ago benzinga.com
Teva Pharmaceutical Industries Subsidiary And Medincell Says European Medicines Agency Has Accepted The Marketing Authorization Application For Olanzapine Long-Acting Injectable (TEV-'749) For The Treatment Of Schizophrenia In Adults
The olanzapine long-acting injectable (TEV-'749) is designed to deliver the efficacy of olanzapine in a subcutaneous formulation1 administered every four weeks.If approved, TEV-‘749 could help fill a…
-
14 years ago benzinga.com
New Kids On The Block: Global X's Top New ETFs
New Kids On The Block: Global X's Top New ETFs
-
15 years ago benzinga.com
Five Multi-Country EM ETFs To Consider
Five Multi-Country EM ETFs To Consider